ArticlemBio2018
Genomic and Geographic Context for the Evolution of High-Risk Carbapenem-Resistant
Article in mBio, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 110 citations in OpenAlex.
- Natural Product-Based Strategies for Combating Antimicrobial Resistance in ESKAPE Pathogens.Current microbiology · 2026Review
- Gain and loss of plasmid-borne antibiotic resistance genes are associated with chromosomal resistance presence in Enterobacteriaceae.mSystems · 2026Article
- Genomic characterization ofMicrobiology spectrum · 2026Article
- Carbapenemases: epidemiology, detection and management in a changing global landscape.JAC-antimicrobial resistance · 2026Review
- The ESKAPE Challenge: Understanding Resistance and Exploring Alternative Treatments.Antibiotics (Basel, Switzerland) · 2026Review
- Global genomic and molecular epidemiology of carbapenem-resistant Enterobacter hormaechei.Communications biology · 2026Article
- A New Challenge of Antibiotic-Resistant Bacteria: Carbapenem-ResistantMicroorganisms · 2026Review
- Precise species identification and whole-genome sequencing analysis ofMicrobiology spectrum · 2026Article
- Article
- Carbapenem-resistant enterobacterales in sterile body fluids: ten-year population genomics and clinical risk factors in a tertiary hospital, 2016-2025.Frontiers in cellular and infection microbiology · 2026Article
- High-risk clonal expansion of IMP-producingAntimicrobial agents and chemotherapy · 2025Article
- Surveillance and characterization of carbapenem-resistant Enterobacter cloacae complex from China, 2015-2018.BMC microbiology · 2025Article
- The clinical impact and dissemination of carbapenemase-producingMicrobiology spectrum · 2025Article
- Molecular Epidemiology and Clinical Characterization of Carbapenemase-Producing Enterobacter Species From an International Cohort.The Journal of infectious diseases · 2025Observational
- Isolation and Molecular Characterization of Antimicrobial-Resistant Bacteria from Vegetable Foods.Pathogens (Basel, Switzerland) · 2025Article
- Infections caused by clonal spread of metallo-beta-lactamase-producingMicrobiology spectrum · 2025Article
- Molecular epidemiology and β-lactam resistance mechanisms ofMicrobiology spectrum · 2025Article
- Complete genome sequences of two verona integron-encoded metallo-ß-lactamase (VIM)-producing enterobacterales isolated from dogs in the United States.Microbiology resource announcements · 2025Article
- Article
- Fluoroquinolone resistance in ESKAPE pathogens: evolutionary pathways, one health transmission, and clinical surveillance.Frontiers in microbiology · 2025Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Recent reports have established the escalating threat of carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.